Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 444Lymphoma 55Recurrence 45Neoplasms, Plasma Cell 35Immunoglobulin Light-chain Amyloidosis 34Hematologic Neoplasms 34Smoldering Multiple Myeloma 28Lymphoma, Non-Hodgkin 27Leukemia, Myeloid, Acute 22Leukemia, Lymphocytic, Chronic, B-Cell 21Neoplasms 20Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Hodgkin Disease 18Myelodysplastic Syndromes 17Monoclonal Gammopathy of Undetermined Significance 13Leukemia 12Waldenstrom Macroglobulinemia 11Lymphoma, Mantle-Cell 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Breast Neoplasms 11Prostatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Paraproteinemias 9Ovarian Neoplasms 9Amyloidosis 9Lung Neoplasms 8Leukemia, Plasma Cell 8Primary Myelofibrosis 7Melanoma 7Lymphoma, Follicular 7

Interventions

Hizentra 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Common Variable Immunodeficiency × Plasma cell × 90 days × Clear all
NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
100 enrolled
Plasma cell

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡